12:15 EDT Ionis Pharmaceuticals (IONS) trading resumes
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals announces FDA approval of Dawnzera
- Ionis Pharmaceuticals trading halted, news pending
- Promising Prospects for Ionis Pharmaceuticals: Buy Rating Backed by Olezarsen’s Potential in sHTG Market
- Ionis Pharmaceuticals price target raised to $46 from $45 at UBS
- Positive Outlook for Ionis Pharmaceuticals Driven by Strong Q2 Results and Promising Pipeline Developments